MAM
Kisht by kisht HDFC MF invests emotion into SIPs with a heartfelt twist
MUMBAI: Ever paid an EMI of emotions? Or made a monthly instalment towards someone’s dreams? In its latest campaign, HDFC Mutual Fund asks viewers to rethink the way they look at investing by reminding them that they’ve been investors all along, just not always with money.
Titled ‘Zindagi Ke Liye SIP’, the campaign trades charts and jargon for heart and hustle. It tells the story of a young girl whose life is shaped by a series of small, consistent “investments” made by her family: a mother’s daily encouragement, a teacher’s dedication, a sibling’s quiet sacrifices. Whether it’s “kisht jazbaat ki” (an instalment of emotions) or “kisht sapno ke shuruwat ki” (an instalment of beginnings), each gesture adds up just like a Systematic Investment Plan.
It’s a clever narrative twist that HDFC Mutual Fund uses to sell a bigger truth: that consistency, discipline and long-term thinking aren’t just traits of savvy investors, they’re how we live our best lives. So why not apply the same logic to wealth creation?
Speaking on the campaign launch, HDFC Asset Management Company MD & CEO Navneet Munot said, “Life’s greatest rewards often come from the consistent, thoughtful investments we make in our relationships, dreams, and aspirations. At HDFC Mutual Fund, we believe the same principle applies to financial investments – disciplined contributions through SIPs over a long period lead to achieving financial goals. Our investor education campaign, ‘Zindagi Ke Liye SIP,’ captures this essence beautifully, inspiring people to invest in their future just as they invest in life.”
Far from being a dull finance lecture, the campaign positions SIPs as life’s financial parallel steady, meaningful, and deeply personal. It taps into universal emotions with the kind of insight that could resonate with those who’ve never thought of themselves as investors.
Backed by a full-spectrum media rollout from digital to outdoor to on-ground activations ‘Zindagi Ke Liye SIP’ aims to get Indians thinking about investing not just as a financial act, but a life philosophy. Because at the end of the day, what is a SIP if not a kisht of faith in tomorrow?
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
